Revenue: As of FY2026 Q2, the actual value is USD 388.18 M, beating the estimate of USD 363.23 M.

EPS: As of FY2026 Q2, the actual value is USD 1.11, beating the estimate of USD 0.89.

EBIT: As of FY2026 Q2, the actual value is USD 98.74 M.

The provided 8-K filing by Lantheus Holdings, Inc. indicates that the company announced its financial results for the three and six months ended June 30, 2026, via a press release on August 6, 2026, but the 8-K filing itself does not contain specific financial or operational metrics. All following metrics are derived from the furnished press release.

Worldwide Revenue

Worldwide revenue increased 2.7% to $388.2 million compared to the same period in 2025.

Net Income

GAAP net income was $75.0 million, a decrease of 4.7% compared to $78.8 million in Q2 2025. Adjusted net income (non-GAAP) was $104.9 million, a decrease of 5.1% compared to $110.6 million in Q2 2025.

Operating Income

Operating income increased 13.9% to $100.2 million. Adjusted operating income (non-GAAP) decreased 6.9% to $142.0 million.

Gross Profit

Gross profit was $241,855 thousand, compared to $241,011 thousand in Q2 2025.

Operating Expenses

• Sales and marketing expenses were $82,805 thousand, compared to $41,041 thousand in Q2 2025.
• General and administrative expenses were $20,633 thousand, compared to $66,515 thousand in Q2 2025.
• Research and development expenses were $38,202 thousand, compared to $45,489 thousand in Q2 2025.
• Total operating expenses were $141,640 thousand, compared to $153,045 thousand in Q2 2025.

Segment Revenue

• Sales of PYLARIFY were $240.4 million, a decrease of 4.1%.
• Sales of Neuraceq were $39.6 million.
• Sales of DEFINITY were $88.3 million, an increase of 5.2%.
• Total oncology revenue was $240,366 thousand, a -4.1% change from $250,642 thousand in Q2 2025.
• Total neurology revenue was $39,616 thousand, a 100.0% change from Q2 2025.
• Total cardiology revenue was $88,279 thousand, a 5.2% change from $83,939 thousand in Q2 2025.
• Strategic partnerships and other revenue was $19,919 thousand, a 71.9% change from $11,590 thousand in Q2 2025.
• SPECT revenue was $0, a -100.0% change from $31,874 thousand in Q2 2025.

Cash Flow

Net cash provided by operating activities was $92.2 million. Free cash flow was $89.9 million. Capital expenditures were - $2,335 thousand. Net cash used in investing activities was - $2,023 thousand. Net cash provided by financing activities was $4,505 thousand.

Balance Sheet Highlights (as of June 30, 2026)

Cash and cash equivalents were $593.3 million, compared to $359.1 million at December 31, 2025. The company has access to up to $750.0 million from a revolving line of credit.

Outlook / Guidance

Lantheus Holdings, Inc. is suspending its previously issued full year 2026 financial guidance due to a pending transaction. The company will not be hosting a conference call in connection with its second quarter 2026 results.

Merger Announcement

On August 3, 2026, Lantheus Holdings, Inc. entered into a definitive agreement to merge with Curium, under which Curium US Holdings LLC will acquire all outstanding shares. The transaction involves $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights providing up to $12.00 per share in potential additional cash payments, for a total transaction value of up to approximately $8.0 billion. Lantheus Holdings, Inc.’s Board of Directors unanimously approved the transaction.